Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: A microdialysis study

Journal of Neuroscience Research

Volumn 90, Issue 3, 2012, Pages 588-596

  Ortega, Jorge E ^a,b,c   Katner, Jason ^a   Davis, Richard ^a   Wade, Mark ^a   Nisenbaum, Laura ^a   Nomikos, George G ^a,d   Svensson, Kjell A ^a   Perry, Kenneth W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Hypothalamus; Mice; Microdialysis; Orexin hypocretin; Prefrontal cortex

Indexed keywords

ACETYLCHOLINE; DOPAMINE; HISTAMINE; MONOAMINE; NORADRENALIN; OREXIN 2 RECEPTOR; SEROTONIN;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; FEMALE; GENE DELETION; GENOTYPE; HISTAMINE RELEASE; HYPOTHALAMUS; KNOCKOUT MOUSE; MICRODIALYSIS; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ACETYLCHOLINE; ANIMALS; DOPAMINE; HISTAMINE; HYPOTHALAMUS; MICE; MICE, KNOCKOUT; MICRODIALYSIS; NOREPINEPHRINE; PREFRONTAL CORTEX; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 84855876112     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22781     Document Type: Article

References (49)

1. Aliaga E, Bustos G, Gysling K. 1995. Release of endogenous catecholamines from the striatum and bed nucleus of stria terminalis evoked by potassium and N-methyl-D-aspartate: in vitro microdialysis studies. J Neurosci Res 40: 89-98.
2. Backberg M, Hervieu G, Wilson S, Meister B. 2002. Orexin receptor-1 (OX-R1) immunoreactivity in chemically identified neurons of the hypothalamus: focus on orexin targets involved in control of food and water intake. Eur J Neurosci 15: 315-328.
3. +-induced increases in noradrenaline and dopamine release are accompanied by reductions in the release of their intraneuronal metabolites from the rat anterior hypothalamus. An in vivo brain microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 339: 54-59.
4. Bernard R, Lydic R, Baghdoyan HA. 2006. Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate g protein subtypes in rat pontine reticular formation. J Pharmacol Exp Ther 317: 163-171.
5. Brevig HN, Watson CJ, Lydic R, Baghdoyan HA. 2010. Hypocretin and GABA interact in the pontine reticular formation to increase wakefulness. Sleep 33: 1285-1293.
6. Brown RE, Sergeeva OA, Eriksson KS, Haas HL. 2002. Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin/hypocretin, histamine and noradrenaline). J Neurosci 22: 8850-8859.
7. Burdakov D, Liss B, Ashcroft FM. 2003. Orexin excites GABAergic neurons of the arcuate nucleus by activating the sodium-calcium exchanger. J Neurosci 23: 4951-4957.
8. Cosford RJ, Parsons LH, Justice JB Jr. 1994. Effect of tetrodotoxin and potassium infusion on microdialysis extraction fraction and extracellular dopamine in the nucleus accumbens. Neurosci Lett 178: 175-178.
9. Cutler DJ, Morris R, Sheridhar V, Wattam TA, Holmes S, Patel S, Arch JR, Wilson S, Buckingham RE, Evans ML, Leslie RA, Williams G. 1999. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 20: 1455-1470.
10. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG. 1998. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 95: 322-327.
11. del Cid-Pellitero E, Garzón M. 2011a. Medial prefrontal cortex receives input from dorsal raphe nucleus neurons targeted by hypocretin1/orexinA-containing axons. Neuroscience 172: 30-43.
12. del Cid-Pellitero ED, Garzón M. 2011b. Hypocretin1/orexinA-containing axons innervate locus coeruleus neurons that project to the rat medial prefrontal cortex. Implication in the sleep-wakefulness cycle and cortical activation. Synapse (in press).
13. Devi LA. 2001. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 22: 532-537.
14. Fadel J, Pasumarthi R, Reznikov LR. 2005. Stimulation of cortical acetylcholine release by orexin A. Neuroscience 130: 541-547.
15. Franklin K, Paxinos G. 1997. The mouse brain in stereotaxic coordinates. San Diego: Academic Press.
16. Govindaiah G, Cox CL. 2006. Modulation of thalamic neuron excitability by orexins. Neuropharmacology 51: 414-425.
17. Greco MA, Shiromani PJ. 2001. Hypocretin receptor protein and mRNA expression in the dorsolateral pons of rats. Brain Res Mol Brain Res 88: 176-182.
18. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, Munton RP, Ashmeade TE, Shah AS, Hatcher JP, Hatcher PD, Jones DN, Smith MI, Piper DC, Hunter AJ, Porter RA, Upton N. 1999. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci U S A 96: 10911-10916.
19. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA. 2001. Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 103: 777-797.
20. Hong ZY, Huang ZL, Qu WM, Eguchi N. 2005. Orexin A promotes histamine, but not norepinephrine or serotonin, release in frontal cortex of mice. Acta Pharmacol Sin 26: 155-159.
21. Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O. 2001. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 98: 9965-9970.
22. Ishizuka T, Yamamoto Y, Yamatodani A. 2002. The effect of orexin-A and -B on the histamine release in the anterior hypothalamus in rats. Neurosci Lett 323: 93-96.
23. Karteris E, Randeva HS. 2003. Orexin receptors and G-protein coupling: evidence for another "promiscuous" seven transmembrane domain receptor. J Pharmacol Sci 93: 126-128.
24. Kilduff TS, Peyron C. 2000. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci 23: 359-365.
25. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP. 2002. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27: 949-959.
26. Kukkonen JP, Holmqvist T, Ammoun S, Akerman KE. 2002. Functions of the orexinergic/hypocretinergic system. Am J Physiol Cell Physiol 283: C1567-C1591.
27. Lin JS. 2000. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4: 471-503.
28. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365-376.
29. 2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem 275: 30806-30812.
30. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK. 2001. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435: 6-25.
31. McCormick DA. 1992. Neurotransmitter actions in the thalamus and cerebral cortex and their role in neuromodulation of thalamocortical activity. Prog Neurobiol 39: 337-388.
32. Nakajima W, Ishida A, Ogasawara M, Takada G. 1998. Effect of N-methyl-D-aspartate and potassium on striatal monoamine metabolism in immature rat: an in vivo microdialysis study. Neurochem Res 23: 1159-1165.
33. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K. 1999. Distribution of orexin neurons in the adult rat brain. Brain Res 827: 243-260.
34. Nuñez A, Moreno-Balandran ME, Rodrigo-Angulo ML, Garzón M, De Andres I. 2006. Relationship between the perifornical hypothalamic area and oral pontine reticular nucleus in the rat. Possible implication of the hypocretinergic projection in the control of rapid eye movement sleep. Eur J Neurosci 24: 2834-2842.
35. Orlando G, Brunetti L, Di Nisio C, Michelotto B, Recinella L, Ciabattoni G, Vacca M. 2001. Effects of cocaine- and amphetamine-regulated transcript peptide, leptin and orexins on hypothalamic serotonin release. Eur J Pharmacol 430: 269-272.
36. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS. 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996-10015.
37. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6: 991-997.
38. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573-585.
39. Saper CB, Chou TC, Scammell TE. 2001. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 24: 726-731.
40. Smart D, Jerman J. 2002. The physiology and pharmacology of the orexins. Pharmacol Ther 94: 51-61.
41. Song CH, Chen XW, Xia JX, Yu ZP, Hu ZA. 2006. Modulatory effects of hypocretin-1/orexin-A with glutamate and gamma-aminobutyric acid on freshly isolated pyramidal neurons from the rat prefrontal cortex. Neurosci Lett 399: 101-105.
42. Stanford JA, Giardina K, Gerhardt GA. 2000. In vivo microdialysis studies of age-related alterations in potassium-evoked overflow of dopamine in the dorsal striatum of Fischer 344 rats. Int J Dev Neurosci 18: 411-416.
43. Sutcliffe JG, de Lecea L. 2002. The hypocretins: setting the arousal threshold. Nat Rev Neurosci 3: 339-349.
44. Taheri S, Mahmoodi M, Opacka-Juffry J, Ghatei MA, Bloom SR. 1999. Distribution and quantification of immunoreactive orexin A in rat tissues. FEBS Lett 457: 157-161.
45. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. 2000. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469-474.
46. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, Belousov AB. 1998. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 18: 7962-7971.
47. Vazquez-Prado J, Casas-Gonzalez P, Garcia-Sainz JA. 2003. G protein-coupled receptor cross-talk: pivotal roles of protein phosphorylation and protein-protein interactions. Cell Signal 15: 549-557.
48. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M. 2003. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38: 715-730.
49. Wu M, Zhang Z, Leranth C, Xu C, van den Pol AN, Alreja M. 2002. Hypocretin increases impulse flow in the septohippocampal GABAergic pathway: implications for arousal via a mechanism of hippocampal disinhibition. J Neurosci 22: 7754-7765.